Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025)
Neumora Therapeutics (NMRA) recorded quarterly Asset Writedowns and Impairment of $217000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025) Analysis & Trends
Neumora Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $217000.0 for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $217000.0; the TTM figure through Dec 2025 stood at $217000.0 (changed N/A YoY), while the FY2025 annual figure was $595000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was $217000.0 for Q4 2025 at Neumora Therapeutics.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $217000.0 in Q4 2025 to a low of $217000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Neumora Therapeutics | 320.17 Mn | 320.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 217,000.00 |
| Dec 31, 2025 | 217,000.00 |